Top in rheumatology: Platelet-rich plasma injections, OA drug pipeline
Click Here to Manage Email Alerts
A speaker at the 2021 OARSI World Congress said intraarticular injections of platelet-rich plasma or cell therapies could be effective alternatives to traditional modalities for osteoarthritis. It was the top story in rheumatology last week.
Another top story was about the FDA’s recent rejection of a risk mitigation proposal from Pfizer for tanezumab, a nerve growth factor blocker, and the search for new osteoarthritis treatments.
Read these and more top stories in rheumatology below:
'Personalized' use of platelet-rich plasma injections may be the future of OA treatment
Understanding the complex associations between pain, function and structural factors in the joints may allow clinicians to use intraarticular injections more effectively in osteoarthritis, according to a speaker at the 2021 OARSI World Congress. Read more.
Osteoarthritis drug pipeline rattles as FDA rejects top contender: What comes next?
Progress toward effective drug therapies is often marked with failure; yet even among a host of difficult-to-treat arthritis conditions, osteoarthritis has received a disproportionate share of therapeutic setbacks and disappointing clinical trials. Read more.
FDA warns website to stop unlawful sale of 'unapproved, misbranded' hydroxychloroquine
The FDA has issued a warning letter to an online pharmacy for allegedly selling unapproved and misbranded drugs, including hydroxychloroquine and chloroquine, for the treatment of COVID-19, lupus, rheumatoid arthritis and other diseases. Read more.
Guselkumab exhibits comparable efficacy to IL-17A, TNF inhibitors for psoriatic arthritis
Guselkumab is comparable to interleukin-17A and subcutaneous TNF inhibitors for efficacy and demonstrated a better PASI response relative to other drugs, in patients with psoriatic arthritis, according to a meta-analysis published in Rheumatology. Read more.
Maternal ankylosing spondylitis linked to twofold higher Kawasaki disease risk in children
Maternal ankylosing spondylitis is associated with a 2.02-times higher likelihood of Kawasaki disease in the offspring, according to a research letter published in JAMA Network Open. Read more.